1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)
Ravi A. Madan(National Cancer Institute), James L. Gulley(National Cancer Institute), Sheri McMahon(National Cancer Institute), Shruti U. Gandhy(Texas A&M Health Science Center), Y-T. Tsai(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Marijo Bilušić(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Jenn Marte(National Cancer Institute), Fatima Karzai(National Institutes of Health), Marc R. Theoret(United States Food and Drug Administration), William Dahut, William D. Figg(National Cancer Institute), Anna Couvillon(National Institutes of Health), Phil M. Arlen(National Cancer Institute), J Schlom(Fox Chase Cancer Center), M. Williams(National Cancer Institute)
Cited by 2
Related Papers
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
|Journal of Clinical Oncology|2014|714
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
|Clinical Cancer Research|2021|567
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
|Cancer Immunology Research|2015|456